explore -WSS

explore

author：hotspot 2025-10-01 04:13:14 - browse：67458

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： STAT Virtual Event: JPM Recap, Live!

knowledge

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

Life science postdocs should get big pay hike, NIH panel says

Does Paxlovid work in people vaccinated against Covid

Second xenotransplant done with gene

At JPM 2024, hospital systems pitch financial strength to investors

FDA early review: GLP

focus

explore

leisure time

What does generative AI mean for health care? We asked experts

Hearing on Medicare drug price negotiation gets unusually heated

Hepatitis C has a cure — but many Americans still lack access to it

At JPM 2024, hospital systems pitch financial strength to investors

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC advisers recommend seasonal use of Pfizer RSV shot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

American taxpayers paid $1.8 trillion in health care costs in 2022

Heart attack and stroke risk calculators need revising

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

Ukraine and a new approach to mental health in war

Readout LOUD podcast: possible new ALS drug, artificial wombs

Thermo Fisher plant for manufacturing gene therapies to expand

Nonprofit, backed by Microsoft, to certify AI tools in health care

Thermo Fisher plant for manufacturing gene therapies to expand

JPM pitch from hospitals? Revenue streams outside of patient care

knowledge

explore

explore

focus